 Unum Therapeutics Inc. UMRX, a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unums BOXR1030 expresses a glypican-3 GPC3 targeted CAR and incorporates the novel transgene glutamic-oxaloacetic transaminase 2 GOT2 to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism. 